ArticleTranslational cancer research2026
Efficacy and safety of neoadjuvant chemotherapy combined with concurrent chemoradiotherapy and concurrent chemoradiotherapy alone in locally advanced cervical cancer: a systematic review and meta-analysis.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: There is no conclusive evidence on whether neoadjuvant chemotherapy (NACT) is suitable for locally advanced cervical cancer (LACC). This study aimed to evaluate the efficacy and safety of NACT combined with concurrent chemoradiotherapy (CCRT) and CCRT alone in LACC. This evaluation aims to offer valuable insights for clinical diagnosis and treatment decisions. Methods: A thorough investigation was performed across the CNKI, Medline, Cochrane Library, PubMed, and EMBASE records to search for studies that evaluated NACT in combination with CCRT, as well as CCRT alone, for individuals suffering from LACC. Subsequently, we computed the odds ratios (ORs) along with their respective 95% confidence intervals (CIs). Additionally, we considered the incidence of adverse events in our analysis. Results: The review encompassed 12 eligible randomized controlled trials, comprising a total of 2,609 patients (Experiment: 1,313, Control: 1,296). NACT combined with chemoradiotherapy had higher complete response rate (CRR, OR =2.06, 95% CI: 1.27-3.34) and objective response rate (ORR, OR =2.41, 95% CI: 1.20-4.87), but there was no difference in disease control rate (DCR) and 3-year survival rate. However, leucopenia was more frequent (OR =2.37, 95% CI: 1.09-5.14), and there was no difference in other adverse reactions. Conclusions: Compared with CCRT alone, combined NACT had a higher initial effect on individuals with LACC, rather than a sustained benefit. Taxol and platinum (TP) regimen may be a better option but more attention should be paid to leucopenia. Further prospective studies with larger sample sizes are needed for the development of therapy regimens for LACC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.